The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial.
 
Jin Xia
No Relationships to Disclose
 
Xiangrui Meng
No Relationships to Disclose
 
Yinghua Ji
Research Funding - AoSaiKang (Inst); CSPC Pharmaceutical Group (Inst); Hualan Bio (Inst)
 
Xiuli Yang
No Relationships to Disclose
 
Yong-Gui Hong
No Relationships to Disclose
 
Junsheng Wang
No Relationships to Disclose
 
Donghai Cui
No Relationships to Disclose
 
Zhiquan Luo
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose